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To better understand the relationship between epitope variation and tumor escape from immune surveillance, SV40 T antigen-transformed B6/
K-0 cells were subjected to selection with individual CTL clones specific for the SV40 T antigen H-2Db-restricted epitopes I or V. CTL-resistant
populations were isolated from a majority of the selection cultures and substituted epitope sequences were identified within most of the resistant
populations. Tag sequences deleted of all or portions of the selection-targeted epitope were identified, but in lower numbers compared to epitope
sequences bearing single residue substitutions. Relatively few flanking residue substitutions were identified, and only in epitope I-targeted
selections. The diversity (numbers and epitope residue locations) of substituted epitope residue positions varied between selections. These findings
suggest that the scope of spontaneously occurring mutations that could allow for escape from individual CD8+ T cell clones is large.
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Multiple factors may influence the success of tumor control
by cellular immunity (Dunn et al., 2002; Khong and Restifo,
2002). While general defects in the processing and presentation
of MHC class I-restricted antigens may facilitate tumor
progression, mutations that remove or alter a critical CD8+ T
lymphocyte-restricted epitope may facilitate tumor escape
under conditions where a relatively narrow, or oligoclonal
cellular immune response focuses primarily on one immuno-
dominant epitope within a single tumor antigen (Bai et al.,
2003; Charini et al., 2001; Coulie et al., 2001; Dudley et al.,
2002; Mortara et al., 1998; Pewe and Perlman, 1999; Turner and
Carbone, 1998). Epitope loss may be achieved by deletion of
sequences encoding the epitope (Akilesh et al., 2001; Dudley
and Roopenian, 1996; Lill et al., 1992), or by amino acid
substitutions that block processing of the intact determinant⁎ Corresponding author. Fax: +1 717 531 6522.
E-mail address: sst1@psu.edu (S.S. Tevethia).
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doi:10.1016/j.virol.2007.02.007(Theobald et al., 1998; Yellen-Shaw et al., 1997). Single amino
acid substitutions that alter primary or secondary MHC anchor
residues, alter peptide conformation so as to prevent efficient
MHC binding, or alter critical TCR contact residues within the
determinant can prevent recognition (Bai et al., 2003; Lill et al.,
1992; Lippolis et al., 1995; Mylin et al., 1995b). An alternative
possibility is that production of an altered peptide ligand (APL)
may functionally antagonize tumor-reactive cytotoxic T
lymphocytes [CTL (Loftus et al., 1998)]. By providing a local
shielding influence, such antagonist epitopes could interfere
with the recognition of wild-type peptide-MHC complexes on
the same or neighboring cells. Examples of such escape
mechanisms have been documented in viral systems (Borrow
and Shaw, 1998; Klenerman et al., 2002; Mortara et al., 1998).
Nonetheless, it remains unclear which mechanism(s) will favor
escape from CTL surveillance for tumors where alteration of
target epitopes within a chromosomally encoded oncoprotein is
required.
To investigate mechanisms of tumor cell escape from onco-
protein-specific CTL, we have used a panel of Simian virus 40
Table 1
Epitope specificity, TCRβ usage and epitope substitutions that illustrate
differences in fine specificity for SV40 Tag-specific CTL clones used in this
study
CTL clone a Restriction SV40 Tag epitope
specificity
TCRβ b Fine
specificity c
Y-1 H-2Db I 7 S206T
A207G
N209T
K-11 H-2Db I 10 A212G/C
Q213H
K-19 H-2Db II/III 10 NAd
Y-5 H-2Db V 7 Q489A
H-1 H-2Db V 9 D495A
a References for the derivation and characterization of each of the CTL clones
are provided in the text.
b For additional information, see Mylin et al. (2000).
c Substituted epitope sequences which are differentially recognized by these
pairs of CTL clones. For further information regarding the fine specificities of
the epitope I-specific CTL clones Y-1 and K-11, see Lippolis et al. (1995) and
Tevethia et al. (1998). The epitope V-specific CTL clones Y-5 and H-1 displayed
differential recognition of alanine substituted synthetic peptides (Mylin and
Tevehia, unpublished).
d Not applicable.
156 L.M. Mylin et al. / Virology 364 (2007) 155–168large T antigen (SV40 Tag)-specific CTL clones (Campbell et
al., 1983; Mylin et al., 1995a; Tanaka et al., 1988, 1989) and
SV40 Tag-transformed B6/K-0 cells (Tanaka and Tevethia,
1988). The 708 residue SV40 Tag oncoprotein promotes
cellular transformation in vitro and tumor progression in vivo
by mechanisms which include dominant interference with cell
cycle regulators (Fanning, 1992; Manfredi and Prives, 1994).
The Tag induces a vigorous MHC class I-restricted response
(Tevethia et al., 1980). The SV40 Tag contains four CD8+ T
lymphocyte epitopes, designated epitopes I, II/III, IV and V,
which display varying immunological potencies in H-2b mice
(Campbell et al., 1983; Deckhut et al., 1992; Lippolis et al.,
1995; Mylin et al., 1995a, 1995b; Tanaka et al., 1988, 1989).
Epitopes I, II/III and Vare H-2Db-restricted, while epitope IV is
presented by H-2Kb molecules. The hierarchy of CD8+ T cell
responses directed at the individual epitopes has been defined
by direct enumeration as IV>I>II/III>V (Mylin et al., 2000).
Epitope V has been characterized as immunorecessive because
epitope V-specific CD8+ T cells are undetectable following
immunization with the wild-type Tag (Fu et al., 1998; Mylin et
al., 1995a, 2000; Tanaka et al., 1989).
SV40 Tag-transformed B6/K-0 cells have been used
previously to isolate CTL escape variants in vitro (Lill et al.,
1992; Tanaka and Tevethia, 1988; Tanaka and Tevethia, 1990).
B6/K-0 cells contain a single chromosomally integrated SV40
Tag gene and consistently express high levels of both cell
surface H-2Db and H-2Kb MHC class I molecules (Tanaka and
Tevethia, 1988). Previous in vitro selections of SV40 Tag-
transformed B6/K-0 cells with epitope I, II/III, IV, or V-specific
CTL clones yielded CTL-resistant variant cell populations
expressing Tags harboring substitution or deletion mutations
affecting the respective, epitope-coding regions (Lill et al.,
1992; Mylin et al., 1995b; Tanaka and Tevethia, 1988, 1990).
Single residue substitutions, were identified in epitope II/III, IV,
or V (Lill et al., 1992; Mylin et al., 1995b). The results of
analyses that utilized corresponding substituted synthetic
peptides supported roles in TCR recognition or peptide-MHC
binding for most of the affected residue positions (Lill et al.,
1992; Mylin et al., 1995b). By contrast, escape variant Tags
selected in the same study by the epitope I-specific CTL clone
Y-1 contained only epitope I deletions (Lill et al., 1992).
Because only a limited number of mutants were isolated and
characterized in the initial study, it was important to conduct a
more comprehensive analysis.
We report here the results of multiple, larger scale, in vitro
CTL selections that individually targeted the H-2Db-restricted
SV40 Tag epitopes I and V. While sharing limited amino acid
similarity, epitopes I and V differ dramatically in immunogeni-
city and the half lives of cell surface MHC complexes bearing
synthetic epitope I or V peptides differ dramatically (Fu et al.,
1998; Mylin et al., 1995a, 2000). Multiple CTL clones specific
for each epitope have been established which express distinct T
cell receptors (TCRs) (Mylin et al., 2000) and display distinct
fine specificities (Deckhut et al., 1991; Lippolis et al., 1995;
Tevethia et al., 1998) (Mylin and Tevethia, unpublished). By
this approach, many additional naturally occurring substitutions
and/or deletions were identified within (or surrounding)epitopes I and V. Our in vitro selection results imply that
spontaneous mutations affecting target epitopes within non-
essential regions of single copy tumor antigens may compro-
mise immunotherapy strategies that target single epitopes with a
limited number of TCR clonotypes.
Results
Analysis of epitope I escape variant sequences
Selections for epitope I variants were conducted with the two
epitope I-specific CTL clones Y-1 and K-11 which express
different TCRs that display distinct fine specificities [Table 1
(Tevethia et al., 1998)]. Two selections were performed using the
CTL clone Y-1. Analysis of epitope I sequences amplified from
the initial set of Y-1-resistant populations (41–52; Fig. 1) that
were selected fromB6/K-0 cells revealed that all harbored one or
two nucleotide substitutions affecting codon 214 of epitope I
(K214N or K214T; Fig. 2A). Residue K214 serves as a TCR
contact residue for both CTL clones, and substitutions affecting
residue 214 abrogate recognition by the CTL clones Y-1 or K-11
(Lippolis et al., 1995). Four different in-frame deletions also
were identified in which a total of 130 (Δ133–262), 165
(Δ138–302), 168 (Δ141–308), or 176 (Δ138–313) codons
had been lost, eliminating epitope I (Fig. 2A). These results
demonstrate that the CTL clone Y-1 can select in vitro for
epitope I variants bearing single amino acid substitutions as
well as large deletions encompassing the epitope.
A second selection was performed using the CTL clone Y-1
because only a limited number of different spontaneous
substitutions were identified within epitope I in the first
selection, and it was important to demonstrate that such epitope
substitutions could arise independently. The second Y-1
selection was initiated with six cultures seeded with B6/K-0
Fig. 1. Escape variant selections. Escape variant populations were selected from B6/K-0 cells or B6/K-0-derived subclones (arrows) by the SV40 Tag-specific CTL
clones H-1, Y-5, K-11 or Y-1. Two Y-1 selections and two K-11 selections were conducted (first, second). Numbers appearing in parentheses located on the arrows
indicate, respectively, the total number of individual cultures used to begin each selection (multiple parallel cultures seeded with B6/K-0 cells, or cultures seeded with
individual B6/K-0-derived subclone lines). The numbers or designations shown below a CTL clone represent designations given to the individual CTL-resistant
variant populations that emerged. Numbers set off by an angled line indicate a focus or island that was expanded from within a selection culture. The “p” designation
for K-11-selected populations indicates that a secondary K-11 exposure (purge) was done for a portion of the resistant population following initial confluence of the
primary selection culture. The identity of the B6/K-0 subclones used to seed selection cultures from which resistant populations emerged is indicated in parentheses
beside the numeric designation for the corresponding resistant population.
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individual B6/K-0 cells. Substitutions isolated by selection from
individual B6/K-0 subclones would represent independently
occurring mutations. Y-1-resistant populations were obtained
from each of the cultures seeded with B6/K-0 cells, and four of
the twelve cultures seeded with the B6/K-0-derived subclones
(Fig. 1). Interestingly, this second CTL clone Y-1 selection
yielded a different set of variant mutations (compare Figs. 2A
and B). Most notably, substitutions affecting TCR contact
residue K214 were not detected in the second Y-1 selection (Fig.
2B). Instead, two substitutions, N201D and N210S affecting
residue N210 which is absolutely required for efficient H-2Db
binding by the epitope I peptide (Lippolis et al., 1995), were
identified in three of six selection cultures seeded with B6/K-0
cells or in the resistant population selected from the B6/K-0-4
subclone. (See Fig. 1 for information about selection cultures in
which variant populations arose, Fig. 2B for the locations of
epitope I residues affected by those mutations, and Fig. 4B for
epitope I sequences identified in each of the variant popula-
tions.) Two substitutions, L215Vor L215M, altered the identity
of the epitope I carboxyl terminal anchor residue position; such
conservative substitutions would not be expected to abrogate
MHC binding of the altered peptide (Lippolis et al., 1995).
Substitutions were identified in three positions (209, 211 and
213) that have been previously implicated as TCR contact
residues (Lippolis et al., 1995). Three doubly mutated epitope I
region sequences were also identified. Two of the doublemutations included substitutions of the central anchor residue
(N210D/V205M and N210S/Y211N; Fig. 2B) which by itself
would be expected to abrogate Y-1 recognition (Lippolis et al.,
1995). The third double mutation (L215M/C216G) included a
conservative substitution (L215M) of the C terminal anchor
residue combined with a substitution of residue 216 (C216G)
which flanks the C terminus of epitope I (Fig. 2B). Two of the
three double mutations included a substitution that affected an
epitope I flanking residue (C216G or V205M; Fig. 2B);
however, variant sequences containing single substitutions
affecting only epitope I flanking residues were not identified
in this Y-1 section. Two deletions that removed epitope I with a
total of either 122 (Δ134–255) or 74 (Δ157–220) Tag residues
were identified in the second Y-1 selection. These results reveal
dramatic differences in the diversity and locations of substitu-
tion mutations, including TCR contact and MHC anchor
residues, were identified in the two Y-1 selections.
To investigate how TCR fine specificity may influence the
diversity of escape variant mutations, additional selections of
B6/K-0 cells and B6/K-0 subclones were conducted using a
second epitope I-specific CTL clone, K-11 (Fig. 1; Table 1). K-
11-resistant populations developed within most of the cultures
seeded with B6/K-0 cells (209–216; 253–256) and approxi-
mately half of those seeded with individual B6/K-0 subclones
(241–252). Mutations identified in the K-11-resistant popula-
tions included substitutions affecting epitope I positions 208,
209, 210, 211, 214 and 215 (Figs. 2C, D). A K214T substitution
Fig. 2. Alterations affecting epitope I identified following selection with the CTL clones Y-1 (A, B) or K-11 (C, D). (A) First Y-1 selection. (B) Second Y-1 selection.
(C) First K-11 selection. (D) Second K-11 selection. Nucleotide and amino acid sequences (single letter abbreviations) for an epitope I 10mer peptide are shown. The
vertical location of each residue in the stick and ball representation implies function within the epitope peptide based on previous studies (Lippolis et al., 1995):
residues implicated in peptide-MHC binding are lowered; residues involved in TCR recognition are raised. Darkened circles indicate residue positions at which
substitutions were identified in this study; nucleotide alteration(s) and predicted amino acid substitutions are shown below the corresponding residue position (arrows).
Deletions affecting epitopes are illustrated by diagrams of the 708 residue Tag, and the residues lost by each deletion are indicated. Numbers not within brackets
indicate residue positions within the wild-type Tag. Bold numbers within the “{}” brackets to the left of the wild-type epitope sequences indicate the total number of
selection cultures from which resistant populations arose. Numbers in brackets to the right of each substitution or deletion shown below the ball and stick epitope
sequence indicate the number of selection cultures in which that substitution or deletion was detected. Positions of altered adjacent flanking residues (shaded and
crosshatched, but not connected by lines to the epitope I residues 206–215) are included in panels B and C. Residue positions altered in doubly mutated epitope
sequences are connected by the dashed lines and indicated by asterisks. The epitope I mutations are also presented Fig. 4 grouped by the variant populations in which
they were identified.
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K-11 selection (Figs. 2C and 4C) while the K214N
substitution, which was prevalent in the first Y-1 selection,
was not detected in the first set of K-11-resistant populations
(compare Figs. 2A and C). However, the K214N substitution
was selected from B6/K-0 cells and the B6/K-0-3 subclone in
the second K-11 selection (Fig. 2D). Large in-frame deletions
that removed both epitopes I and II/III (Δ182–236, Δ137–
254) were identified in two K-11-resistant populations (212,
254; Figs. 2C and D), while a third and smaller in-frame
deletion was identified that inactivated epitope I but retained
epitope II/III (Δ200–212; Fig. 2D). Epitope I sequences
bearing two substitutions within the epitope sequence were
identified in two K-11-resistant populations (209 and 213;
Fig. 2C); both contained an alteration of the TCR contact
residue position 214 in addition to a substitution affecting an
anchor residue (K214T/L215S and N210I/K214R). Singlesubstitutions affecting only the C terminal flanking residue
(C216S, C216R) were identified in two K-11-resistant
populations. Unlike the Y-1-selected flanking residue sub-
stitutions (see above; Fig. 2B), the position 216 substitutions
selected by the CTL clone K-11 appeared as single mutations
(Fig. 2C). Together, these results show that, under appropriate
conditions, epitope I-specific CTL clones can select in vitro
for epitope I variants containing single residue substitutions
that occur within the epitope or flank the epitope in addition
to variants that have been deleted of the epitope.
Analysis of epitope V escape variant sequences
SV40 Tag epitope V is immunorecessive (Mylin et al., 1995a,
2000; Tanaka et al., 1989). Epitope V is presented on H-2Db
MHC class I molecules on the surface of SV40 Tag-transformed
cells and cells infected by vaccinia virus recombinants encoding
Fig. 3. Alterations affecting epitope V identified following selection with the
CTL clones H-1 (A) or Y-5 (B). See legend of Fig. 2 for explanation of numbers
and symbols. Deletions affecting epitope Vare illustrated by diagrams of the 708
residue Tag; amino acid sequences retained in the deleted Tags are shown in
plain text (below the Tag diagram) while Tag residues lost by the deletion are
indicated in italic and within parentheses. (A) H-1-selected deletionsΔ474–489
and Δ486–489, and the Q489E and Q489L substitutions, respectively, are
highlighted by one or two asterisks because they represent the same altered
epitope sequences. The epitope V mutations are also presented in Fig. 5 grouped
by the variant populations in which they were identified.
159L.M. Mylin et al. / Virology 364 (2007) 155–168the full-length Tag or epitope V minigenes (Fu et al., 1998).
Nonetheless, epitope V remains nonimmunogenic within Tag
derivatives that retain subsets of the immunodominant Tag
epitopes (Fu et al., 1998; Mylin et al., 1995a, 2000). Epitope V is
also of interest due to its escape from negative selection in Tag
transgenic mice where central tolerance leads to the deletion of
CD8+ T cells specific to the dominant Tag epitopes due to
thymic expression of Tag (Schell, 2004; Schell et al., 1999).
Epitope V-specific T cells can be activated in SV11 transgenic
mice upon appropriate immunization (Ryan and Schell, 2006;
Schell, 2004).
Variant selections were conducted with the two epitope V-
specific CTL clones Y-5 and H-1 which express distinct TCRs
[Table 1 (Mylin et al., 1995a, 2000; Tanaka et al., 1989)]. All
selection cultures initiated with the epitope V-specific CTL
clones H-1 or Y-5 yielded resistant populations. Selection by the
CTL clones Y-5 or H-1 revealed many variant sequences that as
a group represented nucleotide substitutions or deletions
affecting five of nine epitope V residues (Figs. 3A and B).
Nucleotide substitutions affecting Tag amino acid residues 489,
491, 492, 496, and 497 were identified within variants selected
by the CTL clone Y-5 (Fig. 3B), while substitutions affecting
amino acid residues 489, 491, 492, 493, and 496 were identified
within H-1-resistant populations (Fig. 3A). Therefore, each of
the CTL clones Y-5 and H-1 selected for mutations affecting
Tag residues 489, 491, 492, and 496. Even so, the nucleotide
alterations and predicted amino acid substitutions affecting
these four commonly substituted epitope V positions often
differed between the populations selected by the two CTL
clones (compare Figs. 3A and B). The diversity of variant
epitope V sequences is further underscored by the fact that two
or more different substitutions were selected at each of four
epitope V residue positions by either CTL clone (codons 489,
491, 492, and 493; Figs. 3A and B). Although the majority of
the predicted amino acid substitutions identified in the variant
epitope V sequences affected non-MHC anchor residues, at
least one anchor residue substitution was selected by Y-5 or H-1
(Figs. 3A and B). The CTL clone H-1 selected for substitutions
affecting the central P5 anchor residue position (N493S,
N493D, N493I) while the CTL clone Y-5 selected for one
substitution affecting the CΩ anchor position (L497F). There-
fore, an array of amino acid substitutions affecting epitope V
was selected by two distinct SV40 Tag epitope V-specific CTL
clones. Differences in TCR clonotype may have contributed to
the selection of distinct sets of epitope variants by the CTL
clones H-1 and Y-5.
Short in-frame deletions affecting the epitope V region of Tag
were selected by both Y-5 and H-1. These deletions removed one
or more epitope V codons along with three or more amino
terminal flanking codons (Figs. 3A and B). For two deletions
selected by the CTL clone H-1, elimination of sequences 5′ to
Gly 490 (the P2 residue) resulted in the replacement of the P1 Gln
489 codon of epitope V with codons specifying either a Glu or
Leu residue (Fig. 3A). A small in-frame deletion selected by the
CTL clone Y-5 removed 6 of 9 epitope V codons and three amino
terminal flanking residues (Fig. 3B). Variant sequences repre-
senting C-terminal deletions of epitope V were not detected. It isunclear if these deletions were not selected, or whether the
annealing locations for the oligonucleotide primers used in this
study to amplify the epitope V region of Tag, or reduced growth
rate for cells expressing Tag genes bearing such deletions may
have prevented detection of 3′ epitope V deletions (Kierstead and
Tevethia, 1993). These results imply that a wealth of substitutions
affecting TCR contact or residues within epitope V are readily
selected by CTL clones in vitro.
Recognition of CTL-selected populations and altered epitope
peptides
A large number of different epitope mutations were
identified within the collection of variant populations selected
in this study. It was important to determine the mechanism(s) by
which the epitope alterations prevented destruction by the
selecting CTL clones.
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(41–52), all of which contained either a substitution affecting
residue 214 or were deleted of epitope I, were not lysed by
either of the epitope I-specific CTL clones (Y-1 and K-11). Each
of the selected populations was lysed efficiently by the epitope
II/III-specific CTL clone K-19 (Fig. 4A) suggesting that H-2Db-
restricted processing and presentation remained intact in the
escape variant populations and that epitope I-specific defects
accounted for the resistance of these variant populations. By
contrast, a majority of the populations derived by the second
Y-1 selection (60–69) showed only marginally reduced levels of
lysis by the CTL clone Y-1 (or near normal lysis by the CTL
clone K-11) relative to that of unselected control B6/K-0 cells
(Fig. 4B); K-19 reactivity towards the same Y-1-selected
populations was comparable to that of the control B6/K-0 cells
(Fig. 4B). The majority of substitutions identified in the same
variant populations are known to affect residues that are critical
for CTL recognition (Lippolis et al., 1995), but a significant
number of unaltered (wild type) epitope I sequences were
amplified from most of the same populations (Fig. 4B). The
minor reduction in Y-1 (or K-11) lysis for these populations
likely indicated that a significant number of cells that retained
wild-type epitope I sequences remained within the CTL-
selected populations.
K-11-resistant populations (209–216) were characterized for
lysis by the CTL clones K-11, K-19 and H-1. The cytotoxicity
assay results shown in Fig. 4C revealed that these populations
were no longer recognized by the CTL clone K-11. With the
exception of population 212, loss of K-11 reactivity from the
selected populations occurred with little apparent reduction in
lysis by epitope II/III- or V-specific CTL clones. Specific
reduction of K-11 lysis for the majority of the selected
populations was consistent with the prevalence of substituted
epitope I sequences within the same populations (Fig. 4C)
although wild-type epitope I sequences were detected in some
populations.
Each of the epitope V-specific CTL clone H-1-selected
populations was resistant to lysis by either of the CTL clones H-1
or Y-5 in standard cytotoxicity assays (Fig. 5A). The majority of
CTL clone Y-5-selected populations showed resistance to lysis
by Y-5 (Fig. 5B), while several of the Y-5-selected populations
(e.g., 22 and 24) were recognized at varying efficiencies by the
CTL clone H-1 (Fig. 5B). Lysis of the Y-5- or H-1-resistant
populations by either epitope I- or II/III-specific CTL clones was
comparable to that of the wild-type B6/K-0 cells (Figs. 5A and
B). Consistent with the wealth of altered epitope V sequences
amplified from variant populations, the cytotoxicity results
suggest that alterations of epitope V were responsible for the
resistance of the H-1- or Y-5-selected populations to lysis by the
epitope V-specific CTL clones rather than reduced Tag
expression or Tag-independent alteration(s) affecting MHC
class I processing or presentation.
Analysis of substituted epitope I and V peptides
To determine the basis for loss of recognition for CTL escape
variant epitope sequences identified in this study, substitutedsynthetic epitope peptides were used in standard cytotoxicity
assays, and were evaluated for their ability to stabilize MHC
class I molecules on the surface of TAP-defective RMA/s cells.
Owing to the wealth of substitutions identified in this study, it
was feasible to synthesize and study synthetic peptides
corresponding to only a subset of the variant epitope sequences.
Due to the prevalence of K214 substitutions in CTL clone
Y-1- and K-11-resistant populations, substituted synthetic
epitope I peptide variants where asparagine (N), threonine
(T), arginine (R), or glutamic acid (E) substitutions replaced
lysine (K) 214 were analyzed for recognition by the epitope I-
specific CTL clones Y-1 and K-11. The results (Fig. 6A)
indicated that each substitution at position 214 abolished
recognition by the CTL clones Y-1 or K-11. Furthermore,
recognition was not restored for either of the CTL clones when
increased concentrations of the variant peptides were used.
Analysis of H-2Db expression on the surface of MHC class I
antigen presentation-deficient RMA/s cells incubated in the
presence of synthetic epitope I peptides failed to reveal
substantial differences in the ability of the residue 214-
substituted epitope I peptide variants to stabilize H-2Db
molecules relative to that of the wild-type epitope I peptide
(Fig. 6A). These results are consistent with those of previous
studies in which position 214 substitutions have been studied
(Deckhut and Tevethia, 1992; Lippolis et al., 1995). Therefore,
the K214N and K214T epitope I substitutions selected in this
study by the CTL clones Y-1 and K-11 alter a residue which
appears to be critical for TCR engagement by both epitope I-
specific CTL clones.
Our analysis of the epitope V variants was confined to a
set of peptides representing three of the more commonly
detected substitutions (Figs. 3A and B). Synthetic epitope V
peptide variants I491N, N492I, and N493S were analyzed in
standard cytotoxicity assays using the CTL clones Y-5 and
H-1 (Fig. 6B) and were compared to the unsubstituted
epitope V peptide for their ability to stabilize H-2Db
molecules on the surface of RMA/s cells (Fig. 6B). The
results of the cytotoxicity assays revealed that the I491N
(selected by H-1 or Y-5) and N493S (selected by H-1, but
not by Y-5) substitutions dramatically reduced recognition by
the CTL clone H-1 (Fig. 6B); the same substitutions reduced
recognition by the CTL clone Y-5 as 1000-fold higher
concentrations of these peptides were required to trigger lysis
by Y-5 that was comparable to lysis of targets pulsed with
the unsubstituted epitope V peptide (Fig. 6B). Neither H-1
nor Y-5 lysed target cells pulsed with the N492I-substituted
variant (Fig. 6B; selected by H-1). Comparison of these
peptides for H-2Db stabilization revealed that the N492I
variant was more effective than the unsubstituted epitope V
peptide (Fig. 6B). The I491N- and N493S-substituted epitope
V peptide variants did not efficiently stabilize H-2Db
complexes (Fig. 6B). These results suggest that the N492I
substitution likely alters a TCR contact residue that is
required for recognition by both of the CTL clones Y-5 and
H-1, because the N492I-substituted peptide efficiently
stabilized H-2Db molecules, but failed to trigger lysis by
either CTL clone. By contrast, these results imply that the
Fig. 4. Epitope sequences and lysis of Y-1- or K-11-selected populations. Populations (A) obtained from the first Y-1 selection. (B) Second Y-1 selection. (C) First K-11
selection. Numbers (parentheses) and types of epitope sequences isolated from CTL-selected populations are shown. The CTL-selected populations or control cell
lines, B6/K-0 or B6/K-1, -4, -5, were combined with the indicated CTL clones (Y-1, K-11, or K-19 for A and B; K-11, K-19 or H-1 for C) in standard 4-h cytotoxicity
assays.
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Fig. 5. Epitope sequences and lysis of H-1- and Y-5-selected populations. (A) Analyses for H-1-selected populations. (B) Analyses for Y-5-selected populations.
Epitope sequences identified by sequencing recombinant clones representing each CTL-selected population are shown. The numbers in the parentheses indicate the
number of each sequence type that was obtained for that population. Each of the CTL-selected populations or control cell lines (B6/K-0 or B6/K-1, -4, -5) was
combined with the indicated CTL clones (K-11, K-19, H-1 or Y-5) in standard 4-h cytotoxicity assays. Legend for panel A is as shown for panel B.
162 L.M. Mylin et al. / Virology 364 (2007) 155–168reduced lysis observed for the I491N- and N493S-substituted
epitope V peptides likely results from reduced H-2Db binding
and/or an altered conformation of the weakly bound peptide.
Discussion
The results of this study indicate that a large number of
naturally occurring mutations (substitutions and deletions)
affecting two distinct H-2Db-restricted SV40 Tag epitopes, I
and V, can be selected from SV40 Tag-transformed cells by
CTL clones in vitro. While the number of different mutations
identified and the fraction of epitope residue positions affected
in the individual selections varied, the total number of mutations
identified by the strategy used in this study was large and didinclude substitutions (in epitope V: I491F and N496I) and
deletions (a variety that affected the epitope I region) that had
been identified in our earlier variant selections (Lill et al., 1992;
Tanaka and Tevethia, 1988, 1990). The presence of numerous
mutant Tag genes within the B6/K-0 population was not
unexpected as Tag immortalization does lead to increased
genetic instability in rapidly dividing cells (Fanning, 1992;
Hiscott et al., 1980, 1981; Manfredi and Prives, 1994;
Wiesmuller et al., 1996) and the Tag can undergo mutation in
many regions without the loss of immortalization function
(Deckhut and Tevethia, 1992; Kierstead and Tevethia, 1993;
Manfredi and Prives, 1994; Tevethia et al., 1998, 2001;
Thompson et al., 1990). Further, cytotoxicity experiments
employing H2b cells expressing constructed Tag mutants or the
Fig. 6. Target cell lysis by CTL clones and H-2Db stabilization for synthetic peptides corresponding to substituted epitope I or V sequences. RMA cells pulsed with
substituted variant peptides at the concentrations indicated in the figure were combined with the CTL clones Y-1 or K-11 (A), or H-1 or Y-5 (B) in standard cytotoxicity
assays (left two panels in A or B). No, no peptide added. The SMIKNLEYM peptide that efficiently binds H-2Db molecules, but is not recognized by Tag-specific CTL
clones, was used as a control in assays utilizing the epitope V-specific CTL clones. RMA/s cells pulsed with varying concentrations of variant epitope I (A) or epitope
V (B) peptides at the concentrations indicated in the figure were analyzed by flow cytometry following staining for cell surface H-2Db complexes using the
conformation-sensitive monoclonal antibody 28-14-8. A peptide corresponding to an H-2Kb-restricted Herpes simplex virus epitope (HSVI-RR1) was used as a non-
stabilizing control (Con).
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variety of single residue substitutions can abrogate recognition
of SV40 Tag epitope I or V by CTL clones in vitro (Deckhut et
al., 1991; Deckhut and Tevethia, 1992; Lippolis et al., 1995).
The strategy employed in this study was designed to
primarily select for variants containing loss of function
mutations affecting the epitope targeted by the selecting CTL
clone. B6/K-0 cells contain a single integrated SV40 Tag gene
(Tanaka and Tevethia, 1990). Therefore, escape due to mutations
affecting the single copy Tag gene was expected to be favored
relative to escape promoted by mutations affecting genes
required for MHC class I-restricted epitope presentation. The
requirement for Tag function to maintain immortalization of the
B6/K-0 cells made it unlikely that rapidly growing variant cells
would contain an inactivated Tag gene (complete antigen loss)
as has been observed for other tumor-associated antigens (Boon
et al., 1994; Boon and van der Bruggen, 1996; Dudley and
Roopenian, 1996). However, large portions of the Tag can be
altered or lost without compromising immortalization function
(Kierstead and Tevethia, 1993; Tevethia et al., 1998, 2001;
Thompson et al., 1990). Specifically, Tag amino acids 127–250,
the region containing epitope I (206–215), or amino acids which
contain epitope V (489–497) can be deleted without compro-mising immortalization or tumorigenicity in immunocompro-
mised mice. Because inactivation of one epitope within a single
Tag gene could provide for escape from a given CTL clone, two
classes of epitope variants could be expected: (1) loss-of-
recognition mutations which impaired epitope recognition due
to epitope deletion, substitution of critical MHC or TCR contact
residues, or alterations which severely reduced epitope proces-
sing; (2) functional interference mutants where target cell
recognition and lysis were compromised by substitutions which
resulted in the production of TCR antagonist peptides. Based on
the results of previous cytotoxicity studies involving Tag
mutants and substituted Tag determinant peptides (Deckhut
and Tevethia, 1992; Lill et al., 1992; Lippolis et al., 1995;
Tevethia et al., 1998) and the analysis of a limited number of
substituted peptides in this study, the majority of substitutions
identified in the current study are likely to represent loss-of-
recognition mutations.
The variety of variant epitope sequences selected by the
SV40 Tag epitope I- or V-specific CTL clones in this study
agree well with the results of previous studies in which altered
Tag derivatives were analyzed for recognition by CTL clones.
In the current study, single residue substituted epitope I variants
were selected by both the epitope I-specific CTL clones (Y-1 or
164 L.M. Mylin et al. / Virology 364 (2007) 155–168K-11). Two Y-1 selections yielded substitutions affecting Tag
epitope I residues 209, 210, 211, 213, 214, and 215, while the
CTL clone K-11 selected for substitutions affecting residues
208, 209, 210, 211, 214 and 215 (Fig. 2). Based on previous
studies, these residue positions have been assigned roles as
either TCR contact or MHC anchor residues (Lippolis et al.,
1995). Lippolis et al. (1995) have previously demonstrated that
neither of the CTL clones Y-1 nor K-11 lysed Tag cell lines
engineered to express substitutions at epitope I positions 206,
207, 210, 211, or 214. Even so, not all substitutions at these
positions are expected to abrogate recognition by epitope I-
specific clones (Deckhut et al., 1991; Lippolis et al., 1995).
Recognition of Tag-transformed cell lines by Y-1 or K-11 can be
differentially affected by substitution of residues 206, 207, 209,
212, or 213 [Table 1 (Lippolis et al., 1995; Tevethia et al.,
1998)]. Therefore, with the exception of residue position 206,
our larger scale selection strategy yielded substitutions in a
majority of epitope I residue positions where substitutions had
been previously shown to abrogate recognition of endogenously
processed Tag epitopes by the CTL clones Y-1 or K-11.
Epitope V variant populations selected by either of the two
CTL clones Y-5 or H-1 in the present study contained a wealth
of substitutions that affected six different epitope V residue
positions. The residues that occupy the altered positions appear
to function as TCR contact, MHC anchor, or conformation
maintaining spacer residues (see Fig. 3 and Fig. 2 legend) based
on the analysis of substituted epitope V synthetic peptides [this
study (Lill et al., 1992); Mylin and Tevethia, data not shown)]
and comparison with published H-2Db:peptide crystal struc-
tures (Young et al., 1994). Mutations previously selected by the
CTL clone Y-5 [N496I in K-5; I491F in K-1, -4, -5 (Lill et al.,
1992; Tanaka and Tevethia, 1990)] were also identified in this
study. The Y-5 CTL clone did not re-select the I491F
substitution in this study, but did select both I491N and
N496I substitution variants. Therefore, the survival advantage
provided by the I491F substitution is not unique to the TCR
expressed by the CTL clone Y-5. Substitutions in a variety of
epitope V positions therefore appear to promote survival during
selection by epitope V-specific CTL clones in vitro.
The results of this study suggest that the role of flanking
sequence variation in escape is minor, or is epitope dependent.
Relatively few flanking sequence substitutions were identified,
and only in the epitope I-targeted selections. Variant sequences
bearing single substitutions affecting the epitope I carboxyl
terminal flanking residue C216 (C216R, C216S) were identified
only following selection with the CTL clone K-11. Two of the
double mutations selected by the CTL clone Y-1 (second
selection) included substitutions affecting flanking residues
(C216G or V205M), however, individual flanking residue
substitutions were not identified in either of the Y-1 selections.
Due to the variety of substitutions that were identified in the
epitope V-targeted selections, it was surprising that flanking
sequence substitutions were not detected. Epitope context
(flanking sequence variation) can, but does not universally
appear to influence CTL clone recognition under the conditions
of standard cytotoxicity assays (Bergmann et al., 1996; Brander
et al., 1999; Del Val et al., 1991; Hahn et al., 1992; Lippolis etal., 1995; Mylin, 1999; Shastri et al., 1995; Yellen-Shaw and
Eisenlohr, 1997; Yellen-Shaw et al., 1997). Specifically,
engineered substitutions affecting native SV40 Tag epitope I
flanking residues did not appear to significantly impair
recognition by the epitope I-specific CTL clones Y-1 or K-11
(Lippolis et al., 1995). However, flanking sequences did
influence CTL recognition and immunogenicity for a single
amino-acid-substituted epitope I variant (S206G) when it was
located in the protein context normally occupied by epitope V
(Mylin, 1999). Conditions used in this study to select CTL
escape variants differ from traditional cytotoxicity assays in that
lower effector to target ratios are used over days rather than
hours. Minor differences in target cell recognition that are not
apparent under the conditions of standard cytotoxicity assays
may nonetheless provide a survival advantage under the in vitro
selection conditions used in this study. Perhaps flanking
sequence substitutions contribute to survival, but individually
are not sufficient to provide for complete long-term resistance.
It should be emphasized that single residue flanking substitu-
tions were identified only as doubly mutated epitope sequences,
or were found as single mutations within resistant populations
in which additional substituted epitope sequences were
identified.
The findings of this study in which CTL clones were used
individually to select and enrich variant cells from monolayer
cultures in vitro may be relevant to immune surveillance and the
control of tumors in vivo. We note that CTL escape variants
have been selected in vivo from transplanted tumors by others
(Bai et al., 2003). In that study, substituted P1A epitope
sequences were identified within CTL-resistant tumor cells that
grew out from tumors following transplantation into immuno-
logically compromised mice and selection with adoptively
transferred P1A-specific transgenic CD8+ T cells (Bai et al.,
2003). Substituted P1A sequences expressed by the CTL-
resistant variants contained one of four single residue substitu-
tions that affected residues located primarily in the carboxy
terminal half of the epitope. The corresponding synthetic
substituted peptides appeared to be compromised in TCR
recognition and, in some cases, MHC association, but failed to
demonstrate antagonist function in vitro (Bai et al., 2003).
Escape variants were not obtained in that study when CTL
populations representing a repertoire of naturally occurring
P1A-specific clonotypes were used. It remains to be determined
if the SV40 Tag escape variant substitutions identified in this
study will promote survival under conditions of CTL selection
in vivo.
Our results imply that the potential for tumor escape
variation by cells transformed by a single copy of the SV40
Tag gene is high. Escape variants emerged following selections
targeted at the stably bound determinant, epitope I, or the more
weakly binding epitope, epitope V. Further studies will be
required to determinewhether biological properties of an epitope
and/or the quality (avidity or aggressiveness) of tumor-specific
CTL do influence the variety or frequency of escape variant
mutations. Such considerations are relevant to immunological
therapy of tumors in hosts where tumor-induced tolerance
progressively eliminates or anergizes high avidity clonotypes
165L.M. Mylin et al. / Virology 364 (2007) 155–168reactive towards immunodominant determinants (Ryan and
Schell, 2006; Schell, 2004; Schell et al., 1999, 2000; Schell and
Tevethia, 2001; Staveley-O'Carroll et al., 2003). The results of
this study imply that strategies that seek to recruit CD8+ T cells
specific for weaker binding determinants, for which tumor-
induced tolerance may be incomplete, may be frustrated by a
high rate of escape variation in the targeted determinant.
Alternately, it may be difficult to eliminate unmutated tumor
cells when targeting weaker epitopes. Epitopes I and V within
SV40 Tag will provide appropriate models to test such
possibilities.
Materials and methods
Cell lines and viruses
The SV40-transformed cell lines B6/K-0 (Tanaka and
Tevethia, 1988) and B6/WT-19 (Tevethia, 1984) were derived
from the cells of C57BL/6 (H-2b) mice. The B6/K-1, -4, -5
cell line was derived by sequential rounds of selection of B6/
K-0 cells with the SV40-Tag-specific CTL clones Y-1, Y-4,
and Y-5 (Tanaka and Tevethia, 1988, 1990). For this study,
twelve single-cell-derived subclones were established from
the B6/K-0 cell line (referred to as B6/K-0 population in the
text) by limiting dilution plating. The B6/K-0 subclones were
shown by flow cytometry to express levels of cell surface
MHC class I molecules (H-2Db and H-2Kb) comparable to
that expressed by the parental B6/K-0 line (not shown). The
parental B6/K-0 line and the subclones were lysed with
similar efficiencies by SV40 Tag-specific CTL clones under
the conditions of standard cytotoxicity assays (not shown).
The RMA cell line and the antigen processing defective
RMA/s derivative have been described (Karre et al., 1986;
Ljunggren and Karre, 1985).
Growth and maintenance of CTL clones
The derivation and characterization of the SV40-Tag-
specific H-2Db-restricted CTL clones Y-1, K-11, K-19, Y-5,
and H-1 have been described (Campbell et al., 1983; Mylin et
al., 1995a, 2000; Tanaka et al., 1988, 1989). Briefly, CTL clones
were maintained in 12-well tissue culture plates (Costar 3513)
and were subcultured twice weekly in RPMI 1640 medium
(Gibco/Invitrogen) supplemented with either recombinant IL-2
(Amgen, Thousand Oaks, CA) or Rat T Stim Culture
Supplement (Becton Dickson) and gamma-irradiated (10,000
rad) B6/WT-19 (Y-1, K-11, K-19) or B6/K-3, -1, -4 (Y-5, H-1)
cells (Mylin et al., 1995a).
Selection and characterization of CTL clone-resistant variants
Multiple SV40 Tag-transformed B6/K-0 kidney cell mono-
layers were individually subjected to selection by H-2Db-
restricted, SV40 T antigen epitope V- or I-specific CTL clones
that express distinct T cell receptors (Mylin et al., 2000). Y-1
and K-11 selections were also performed using B6/K-0 cells in
parallel with B6/K-0 subclones. The method used in this studyfor selection and molecular analysis of CTL clone-resistant cell
populations from among B6/K-0 cells or B6/K-0 subclones was
modified from that reported in a previous study (Tanaka and
Tevethia, 1988, 1990). Selections were initiated using eight
to twelve freshly confluent monolayers prepared in 75-cm2
flasks. Flasks were individually seeded with up to 107 B6/K-0
cells in Dulbecco's modified Eagle medium supplemented
with 10% heat-inactivated fetal bovine serum (HyClone, Logan,
Utah), 100 U of penicillin per ml, 100 μg of streptomycin
per ml, 2 mM L-glutamine, 100 μg of kanamycin per ml,
20 mM N-2- hydroxyethylpiperazine-N′-2-ethanesulfonic acid
(HEPES), and 0.15% (wt/vol) sodium bicarbonate (DMEM10),
and were incubated at 37 °C with 5% CO2 in a humidified
incubator from 4 h to overnight. The plating medium was
aspirated and replaced with 18 ml of fresh selection medium
after which appropriate numbers of the respective CTL clone
were added to each flask. Selections employing the CTL clones
H-1, Y-5, K-19 and Y-1 were performed in RPMI 1640
medium (Gibco BRL, Gaithersburg, MD) supplemented with
10% heat-inactivated fetal bovine serum (HyClone), 2 mM L-
glutamine, 5×10−5 M β-mercaptoethanol, 25 μg of pyruvic
acid per ml, 100 U of penicillin per ml, 100 μg of streptomycin
per ml, and 5 mM HEPES (CTL medium). K-11 selections
were attempted using either CTL medium or DMEM10; no K-
11-resistant variants were obtained following multiple attempts
in which the RPMI-based CTL medium was used during the
selection. CTL were harvested from culture wells using
versene, pelleted, and resuspended in CTL medium to a
concentration of 0.5–2×106 CTL/ml, and volumes of CTL
representing initial ratios of 0.1 to 0.3 effector CTL per B6/K-0
target cell were added to individual selection flasks. Following
CTL addition, flasks were incubated at 37 °C, 5% CO2 in a
humidified incubator and agitated periodically for 2 to 3 days
after which nonadherent cells and medium were aspirated from
the flasks and replaced with 18 ml of DMEM10. Depending on
the efficiency with which the target cell monolayer had been
disrupted, individual flasks were incubated in medium alone
overnight, or for several days (or weeks) before CTL addition
was repeated. Because the CTL clone K-11 survived and
proliferated in the selection cultures, it was necessary to
routinely reduce the number of viable K-11 CTL in the
selection cultures 1 or 2 days following addition of the CTL
by replacing the selection culture medium with DMEM that
contained 5% (v/v) FBS. CTL additions were routinely
performed up to twice weekly over a period of 3 to 7
weeks by which time a resistant monolayer (or large islands of
resistant cells) had developed, or treatment on an individual
selection culture was discontinued due to the absence of
resistant fibroblast cells. Resistant cell monolayers were
routinely harvested from the primary selection cultures by
trypsinization, and were replated into fresh flasks for
expansion prior to characterization and preservation. Follow-
ing initial trypsinization and replating, most resistant popula-
tions were re-exposed to the selecting CTL clone to remove
residual wild-type B6/K-0 cells. CTL-selected populations
were tested for uniform expression of the Tag by nuclear
immunofluorescence using the monoclonal antibodies 419 and
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(Kierstead and Tevethia, 1993; Thompson et al., 1990) and
were tested for recognition by Tag-specific CTL clones in
standard cytotoxicity assays.
PCR amplification and DNA sequence analysis of variant
epitopes
High molecular weight DNA was prepared from the CTL-
selected populations or unselected B6/K-0 cells by phenol
extraction and ethanol precipitation following overnight
extraction of 1–3×106 trypsinized, PBS-washed cells in the
presence of SDS and proteinase K (Schell et al., 1999). Aliquots
representing less than 3% of the total nucleic acid yield were
subjected to 30 cycles of PCR amplification using primers
which flanked the region of SV40 Tag containing the epitope
recognized by the selecting CTL clone using Perkin-Elmer
models 9600 or 2400 Gene Amp or Techne Genius thermal
cyclers and Taq DNA polymerase (Perkin Elmer or PGC
Scientific). Multiple primer pairs were used for some
amplifications because deletions encompassing the epitope
and its flanking sequences were suspected, or preliminary PCR
reactions performed with closely spaced primers produced no
visible product. The primer pairs (sense and antisense) used to
amplify sequences surrounding Tag epitopes I and II/III or
epitope V and the sizes predicted for full-sized amplification
products were as follows: epitopes I and/or II/III, STEV219 5′-
TCCAACCTATGGAACTGATGAATG-3′ and STEV189 5′-
TAGTTAATTGTAGGCTATCAACCCGC-3′ (820 bp), or
JTEV27 5′-ATGGAAAATATTCTGTAACC-3′ and STEV02
5′-GCTCCTTTAACCCACCTGGC-3′ (238 bp); epitope V,
STEV335, 5′-GAATTATGTGGGGGGAAAGC-3′ and
JTEV03, 5′-TCATGGTGACTATTCCAGGGGG-3′ (264 bp).
Oligonucleotides used for PCR or DNA sequencing were
synthesized by a MilliGen/Biosearch 7500 DNA synthesizer in
the Macromolecular Core Facility of the Pennsylvania State
University College of Medicine, and were routinely purified
prior to use by NENsorb chromatography.
Products of the PCR reactions were visualized by ethidium
bromide staining following electrophoresis on analytical 1 or
2% (w/v) agarose gels. The nucleotide sequences of PCR
products resulting from a subset of epitope V selections were
determined by direct sequencing following a second round of
asymmetric amplification. The majority of individual variant
sequences were identified by sequencing individual PCR
products following their random isolation as recombinant
subclones in the vectors pUC19 (Yanisch-Perron et al., 1985)
or pGEM-T (Promega). PCR products of the predicted size (or
shorter) were excised from preparative agarose gels, purified by
the QIAEX II procedure (Qiagen), concentrated by ethanol
precipitation, dissolved in a minimal volume (0.01 ml) of glass
distilled water, and used for ligation. Candidate plasmids were
screened by restriction digestion for the presence of appropriate
sized inserts and were prepared for DNA sequence analysis by
using the QIAwell8 (Qiagen) or High Pure Plasmid Isolation
(Roche) procedures. DNA sequence analysis of plasmid DNAs
was performed manually using 35S-labeled dATP and dideox-ynucleotide triphosphate terminators (Sequenase, United States
Biochemicals), or by an automated method utilizing fluorescent
terminators that was performed by the Macromolecular
Genetics Core Facility of the Penn State University School of
Medicine. The primers JTEV27 or STEV335, respectively,
were used to sequence recombinant plasmids bearing epitope I
or epitope V region sequences. Sequencing reactions for deleted
epitope regions were primed with either STEV219 or STEV189
(epitopes I, II/II region) or universal primers complementary to
flanking vector sequences.
MHC class I molecule stabilization assay
Synthetic peptides corresponding to wild-type or substituted
SV40 Tag epitope sequences were compared for the ability to
stabilize MHC class I molecules on the surface of MHC class I
presentation-defective RMA/s cells by a flow cytometry assay
as described previously (Fu et al., 1998; Lippolis et al., 1995;
Mylin et al., 1995a) using the H-2Db-specific, conformation-
sensitive monoclonal antibody 28-14-8 (Potter et al., 1984). A
peptide corresponding to the H-2Kb-restricted HSVI-RR1
epitope (Salvucci et al., 1995) was used as a non-binding
control.
Cytotoxicity assays
Conditions for the use of SV40 Tag-specific CTL clones in
cytotoxicity assays have been described (Lippolis et al., 1995;
Mylin et al., 1995a). CTL-selected fibroblast target populations
were labeled with 51Cr, harvested with trypsin, washed, and
combined with graded numbers of selecting or non-selecting
CTL clone effectors. For most assays, fibroblast target cell
populations were pre-treated with gamma interferon (Pharma-
cia) for 2 days to optimize MHC class I presentation (Lippolis et
al., 1995; Mylin et al., 1995a). The conditions used to compare
lysis of RMA cells incubated in the presence of varying
concentrations of synthetic peptides have been described (Fu et
al., 1998). The H-2Db-binding peptide, SMIKNLEYM (Gairin
and Oldstone, 1992) that is not recognized by Tag-specific CTL
(Mylin et al., 1995a) was used as a control. Synthetic peptides
used in this study were synthesized at the Macromolecular Core
Facility of The Pennsylvania State University College of
Medicine by 9-fluorenylmethoxycarbonyl chemistry on an
automated peptide synthesizer (9050 Milligen PepSynthesizer)
or were obtained from Chiron (pin synthesis) and were routinely
used without purification.
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